Erasca (ERAS) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- —
- Estimate
- -$0.11
- Surprise
- —
- Score today
- 5.2/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
Coverage in the report window
- B of A Securities Maintains Neutral on Erasca, Raises Price Target to $20 — benzinga, 2026-08-14
- Guggenheim Maintains Buy on Erasca, Raises Price Target to $21 — benzinga, 2026-08-13
- HC Wainwright & Co. Maintains Buy on Erasca, Raises Price Target to $22 — benzinga, 2026-08-12
Where TrendMatrix's rating stands now
TrendMatrix currently rates ERAS Sell at 5.2/10; no pre/post engine snapshot brackets this report.
0 of the last 4 quarters beat the estimate. Next scheduled report: 2026-11-11.
What argues against it
- Concentration risk — Pipeline: ERAS-0015 and ERAS-4001 Phase 1 programs
- Quality below floor (1.6 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $16.52
- Price target
- $20.98
- Stop
- $14.91
- Upside to target
- +27.0%
- Reward-to-risk
- 2.1:1
Model outputs from TrendMatrix’s engine as of 2026-09-14 — shown for context, not personalized investment advice.
ERAS at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $5.55B
- P/E (fwd)
- -25.5
- 52-week range
- $1.53–$24.28
- Off 52-week high
- 32.0%
- RSI (14)
- 36
- Volume vs avg
- 0.75×
- Score today
- 5.2/10